Effects on health-related quality of life in patients treated with lurasidone for bipolar depression: results from two placebo controlled bipolar depression trials

Krithika Rajagopalan, Elizabeth Dansie Bacci, Daisy Ng-Mak, Kathy Wyrwich, Andrei Pikalov, Antony Loebel, Krithika Rajagopalan, Elizabeth Dansie Bacci, Daisy Ng-Mak, Kathy Wyrwich, Andrei Pikalov, Antony Loebel

Abstract

Background: Depressive symptoms associated with bipolar disorder negatively impact health-related quality of life (HRQoL). The efficacy of lurasidone in reducing depressive symptoms has been previously demonstrated. The objective of this study was to examine the direct and indirect effect (mediated through improvement in depression symptoms) of lurasidone in improving patient HRQoL.

Methods: A secondary analysis of data was conducted of two 6-week, double-blind, placebo-controlled trials assessing the effect of lurasidone (lurasidone monotherapy [20-60 mg/day or 80-120 mg/day]; lurasidone adjunctive to lithium or valproate [20-120 mg/day]) in patients with bipolar depression. Patient HRQoL was measured using the Quality of Life Enjoyment and Satisfaction Questionnaire Short Form (Q-LES-Q SF). Depression symptoms were measured using the Montgomery-Asberg Depression Rating Scale (MADRS). Analysis of covariance (ANCOVA) was used to estimate the effect of lurasidone on improvement in the Q-LES-Q SF percentage maximum score from baseline to 6 weeks. Path analysis was used to evaluate the total effect (β1), as well as the indirect (β2*β3) and direct (β4) effect of lurasidone on Q-LES-Q SF change through improvements in MADRS.

Results: A total of 340 and 485 patients from the monotherapy and adjunctive therapy, respectively, were included in the analysis. At 6-weeks, ANCOVA analyses demonstrated that lurasidone provided significant improvement in adjusted mean Q-LES-Q SF scores in comparison to placebo for monotherapy (22.9 and 22.7 vs. 15.2, both p < 0.01) and adjunctive therapy (23.1 vs. 17.9, p = 0.01). Path analyses indicated that lurasidone treatment predicted MADRS improvement (monotherapy: β2 = -0.44, p < 0.001; adjunctive therapy: β2 = -0.34, p = 0.003), which subsequently predicted improvement in Q-LES-Q SF (monotherapy: β3 = -0.73, p < 0.001; adjunctive therapy: β3 = -0.75, p < 0.001); however, the effect of lurasidone on improvement in Q-LES-Q SF was largely mediated by change in MADRS (monotherapy: β4 = 0.11, p = 0.13; adjunctive therapy: β4 = 0.02, p = 0.77).

Conclusions: Lurasidone as a monotherapy and adjunctive to lithium or valproate is an effective treatment for improving HRQoL in patients with bipolar depression. However, improvement in HRQoL was not independent of improvement in depression, indicating that the effect of lurasidone on improving patient HRQoL may act through a reduction in depressive symptoms associated with bipolar disorder.

Trial registration: Clinicaltrials.gov identifiers: NCT00868699 and NCT00868452 (both registered March 23, 2009).

Keywords: Bipolar disorder; Depression; Drug therapy; Patient functioning; Quality of life enjoyment and satisfaction questionnaire.

Figures

Fig. 1
Fig. 1
a Path analysis model 4: Monotherapy. b Path analysis model 4: adjunctive therapy

References

    1. Merikangas KR, Akiskal HS, Angst J, Greenberg PE, Hirschfeld RM, Petukhova M, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Archives of general psychiatry. 2007;64(5):543–52. doi: 10.1001/archpsyc.64.5.543.
    1. Merikangas KR, Jin R, He JP, Kessler RC, Lee S, Sampson NA, et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Archives of general psychiatry. 2011;68(3):241–51. doi: 10.1001/archgenpsychiatry.2011.12.
    1. World Health Organization. Global Burden of Disease: 2004 Update. Geneva, Switzerland: World Health Organization; 2008.
    1. Michalak EE, Murray G, Young AH, Lam RW. Burden of bipolar depression: impact of disorder and medications on quality of life. CNS drugs. 2008;22(5):389–406. doi: 10.2165/00023210-200822050-00003.
    1. Fagiolini A, Coluccia A, Maina G, Forgione RN, Goracci A, Cuomo A, et al. Diagnosis, epidemiology and management of mixed states in bipolar disorder. CNS drugs. 2015;29(9):725–40. doi: 10.1007/s40263-015-0275-6.
    1. Rosa AR, Reinares M, Michalak EE, Bonnin CM, Sole B, Franco C, et al. Functional impairment and disability across mood states in bipolar disorder. Value in health. 2010;13(8):984–8. doi: 10.1111/j.1524-4733.2010.00768.x.
    1. Malhi GS, Ivanovski B, Hadzi-Pavlovic D, Mitchell PB, Vieta E, Sachdev P. Neuropsychological deficits and functional impairment in bipolar depression, hypomania and euthymia. Bipolar Disord. 2007;9(1–2):114–25. doi: 10.1111/j.1399-5618.2007.00324.x.
    1. Miller S, Dell'Osso B, Ketter TA. The prevalence and burden of bipolar depression. J Affect Disord. 2014;169(Suppl 1):S3–11. doi: 10.1016/S0165-0327(14)70003-5.
    1. Moreno C, Hasin DS, Arango C, Oquendo MA, Vieta E, Liu S, et al. Depression in bipolar disorder versus major depressive disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Bipolar Disord. 2012;14(3):271–82. doi: 10.1111/j.1399-5618.2012.01009.x.
    1. van der Voort TY, Seldenrijk A, van Meijel B, Goossens PJ, Beekman AT, Penninx BW, et al. Functional versus syndromal recovery in patients with major depressive disorder and bipolar disorder. J Clin Psychiatry. 2015;76(6):e809–14. doi: 10.4088/JCP.14m09548.
    1. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382–9. doi: 10.1192/bjp.134.4.382.
    1. Keck PE., Jr Defining and improving response to treatment in patients with bipolar disorder. J Clin Psychiatry. 2004;65(Suppl 15):25–9.
    1. Miklowitz DJ, Otto MW, Frank E, Reilly-Harrington NA, Kogan JN, Sachs GS, et al. Intensive psychosocial intervention enhances functioning in patients with bipolar depression: results from a 9-month randomized controlled trial. Am J Psychiatry. 2007;164(9):1340–7. doi: 10.1176/appi.ajp.2007.07020311.
    1. Piccinni A, Catena M, Del Debbio A, Marazziti D, Monje C, Schiavi E, et al. Health-related quality of life and functioning in remitted bipolar I outpatients. Compr Psychiatry. 2007;48(4):323–8. doi: 10.1016/j.comppsych.2006.12.007.
    1. Rubio JM, Olfson M, Villegas L, Perez-Fuentes G, Wang S, Blanco C. Quality of life following remission of mental disorders: findings from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2013;74(5):e445–50. doi: 10.4088/JCP.12m08269.
    1. Harvey PD. Defining and achieving recovery from bipolar disorder. J Clin Psychiatry. 2006;67(Suppl 9):14–8.
    1. Michalak EE, Yatham LN, Lam RW. Quality of life in bipolar disorder: a review of the literature. Health Qual Life Outcomes. 2005;3:72. doi: 10.1186/1477-7525-3-72.
    1. Revicki DA, Matza LS, Flood E, Lloyd A. Bipolar disorder and health-related quality of life: review of burden of disease and clinical trials. PharmacoEcon. 2005;23(6):583–94. doi: 10.2165/00019053-200523060-00005.
    1. IsHak WW, Brown K, Aye SS, Kahloon M, Mobaraki S, Hanna R. Health-related quality of life in bipolar disorder. Bipolar Disord. 2012;14(1):6–18. doi: 10.1111/j.1399-5618.2011.00969.x.
    1. Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry. 2003;60(11):1079–88. doi: 10.1001/archpsyc.60.11.1079.
    1. Sanford M, Keating GM. Quetiapine: a review of its use in the management of bipolar depression. CNS drugs. 2012;26(5):435–60. doi: 10.2165/11203840-000000000-00000.
    1. Bogart GT, Chavez B. Safety and efficacy of quetiapine in bipolar depression. Ann Pharmacother. 2009;43(11):1848–56. doi: 10.1345/aph.1M193.
    1. Loebel A, Cucchiaro J, Silva R, Kroger H, Sarma K, Xu J, et al. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: A randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014;171(2):169–77. doi: 10.1176/appi.ajp.2013.13070985.
    1. Loebel A, Cucchiaro J, Silva R, Kroger H, Sarma K, Xu J, et al. Lurasidone monotherapy in the treatment of bipolar I depression: A randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014b;171(2):160–8.
    1. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59 Suppl 20:22–33.
    1. Sachs GS. Strategies for improving treatment of bipolar disorder: integration of measurement and management. Acta Psychiatrica Scandinavica Supplementum. 2004;422:7–17. doi: 10.1111/j.1600-0447.2004.00409.x.
    1. Endicott J, Nee J, Harrison W, Blumenthal R. Quality of life enjoyment and satisfaction questionnaire: a new measure. Psychopharmacol Bull. 1993;29(2):321–6.
    1. Baron RM, Kenny DA. The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J Pers Soc Psychol. 1986;51(6):1173–82. doi: 10.1037/0022-3514.51.6.1173.
    1. Muthén LK, Muthén BO. Mplus User's Guide. 7th ed. Los Angeles, CA: Muthén & Muthén; 1998–2013.
    1. Kenny DA. Mediation. 2014. . Accessed 28 Feb 2014.
    1. MacCallum RC, Browne MW, Sugawara HM. Power analysis and determination of sample size for covariance structure modeling. Psychol Methods. 1996;1:130–49. doi: 10.1037/1082-989X.1.2.130.
    1. Hu L, Bentler PM. Cutoff criteria for fit indexes in covariance structure analysis. Conventional criteria versus new alternatives. Structural Equation Modeling. 1999;6:1–55. doi: 10.1080/10705519909540118.
    1. Shi L, Namjoshi MA, Swindle R, Yu X, Risser R, Baker RW, et al. Effects of olanzapine alone and olanzapine/fluoxetine combination on health-related quality of life in patients with bipolar depression: secondary analyses of a double-blind, placebo-controlled, randomized clinical trial. Clin Ther. 2004;26(1):125–34. doi: 10.1016/S0149-2918(04)90013-6.
    1. Endicott J, Paulsson B, Gustafsson U, Schioler H, Hassan M. Quetiapine monotherapy in the treatment of depressive episodes of bipolar I and II disorder: Improvements in quality of life and quality of sleep. J Affect Disord. 2008;111(2–3):306–19. doi: 10.1016/j.jad.2008.06.019.
    1. Endicott J, Rajagopalan K, Minkwitz M, Macfadden W, Bolder Study Group A randomized, double-blind, placebo-controlled study of quetiapine in the treatment of bipolar I and II depression: improvements in quality of life. Int Clin Psychopharmacol. 2007;22(1):29–37.
    1. Goldberg JF, Harrow M, Leon AC. Lithium treatment of bipolar affective disorders under naturalistic followup conditions. Psychopharmacol Bull. 1996;32(1):47–54.
    1. Ghaemi SN, Goodwin FK. Gabapentin treatment of the non-refractory bipolar spectrum: an open case series. J Affect Disord. 2001;65(2):167–71. doi: 10.1016/S0165-0327(00)00218-4.
    1. Nunes MI. The relationship between quality of life and adherence to treatment. J Clin Psychiatry. 2005;66(Suppl 1):24–9.
    1. Velligan DI, Weiden PJ, Sajatovic M, Scott J, Carpenter D, Ross R, et al. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry. 2009;70(Suppl 4):1–46.
    1. Zhang H, Wisniewski SR, Bauer MS, Sachs GS, Thase ME. Systematic Treatment Enhancement Program for Bipolar Disorder Investigators. Comparisons of perceived quality of life across clinical states in bipolar disorder: data from the first 2000 Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) participants. Compr Psychiatry. 2006;47(3):161–8. doi: 10.1016/j.comppsych.2005.08.001.
    1. Vojta C, Kinosian B, Glick H, Altshuler L, Bauer MS. Self-reported quality of life across mood states in bipolar disorder. Compr Psychiatry. 2001;42(3):190–5. doi: 10.1053/comp.2001.23143.
    1. Namjoshi MA, Buesching DP. A review of the health-related quality of life literature in bipolar disorder. Qual Life Res. 2001;10(2):105–15. doi: 10.1023/A:1016662018075.
    1. Saarni SI, Viertio S, Perala J, Koskinen S, Lonnqvist J, Suvisaari J. Quality of life of people with schizophrenia, bipolar disorder and other psychotic disorders. Br J Psychiatry. 2010;197(5):386–94. doi: 10.1192/bjp.bp.109.076489.
    1. Pae CU, Forbes A, Patkar AA. Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data. CNS drugs. 2011;25(2):109–27. doi: 10.2165/11538980-000000000-00000.
    1. Berman RM, Marcus RN, Swanink R, McQuade RD, Carson WH, Corey-Lisle PK, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007;68(6):843–53. doi: 10.4088/JCP.v68n0604.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する